QUIDEL CORPORATION (NASDAQ:QDEL) Files An 8-K Other Events
Item 8.01 Other Events.
presentation of the components of revenue to reflect managements
revised reporting structure of its product lines. In association
with the change, the revenues of QuickVue>and
Sofia>businesses will be reported within the companys
Immunoassay category, and the revenues of Solana, AmpliVue>and
Lyra>products will be reported in the companys Molecular
category. Quidel’s Thyretain and Diagnostic Hybrids, or DHI,
revenues will be reported in the company’s Virology revenue, and
the Specialty Products Group, or SPG, businesses will be reported
in the company’s Specialty Products revenue.
components of revenue, on January 23, 2017, the company posted on
its website schedules providing a recast of quarterly revenues.
These schedules recast the components of quarterly revenue for the
periods ended March 31, 2014 through September 30, 2016 and for the
fiscal years ended December 31, 2014 and 2015. This information
will be presented in future filings on the companys Quarterly
Reports on Form 10-Q and Annual Report on Form 10-K for applicable
comparable periods. The information in this Current Report is being
furnished, not filed, under Item 8.01 in this Current Report on
Form 8-K.
revenue reporting categories on January 23, 2017. A copy of the
press release is attached as Exhibit 99.1 to this current report on
Form 8-K.
|
|
|
|
|
|
|
|
|
(d) Exhibits.
|
|
|||
|
|
|
|
|||
|
|
The following exhibit is furnished with this current
report on Form 8-K: |
|
|||
|
|
|
|
|||
|
|
Exhibit Number
|
Description of Exhibit
|
|||
|
|
|
|
|
|
|
|
|
99.1
|
Press release, dated January 23, 2017
|
|||
|
|
|
|
|
|
|
About QUIDEL CORPORATION (NASDAQ:QDEL)
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The Company’s diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers. It markets its products in the United States through a network of national and regional distributors and a direct sales force. Internationally, it sells and markets primarily through distributor arrangements. Its diagnostic solutions are used in the detection and diagnosis of many critical diseases and other medical conditions, including autoimmune diseases, bone health and thyroid diseases. It provides diagnostic testing solutions under various brand names, including Quidel, QuickVue+ and Thyretain. QUIDEL CORPORATION (NASDAQ:QDEL) Recent Trading Information
QUIDEL CORPORATION (NASDAQ:QDEL) closed its last trading session down -0.04 at 19.19 with 143,904 shares trading hands.
